Literature DB >> 16339845

Evidence for a multivalent interaction of symmetrical, N-linked, lidocaine dimers with voltage-gated Na+ channels.

J A M Smith1, S M Amagasu, J Hembrador, S Axt, R Chang, T Church, C Gee, J R Jacobsen, T Jenkins, E Kaufman, N Mai, R G Vickery.   

Abstract

The interaction of symmetrical lidocaine dimers with voltage-gated Na+ channels (VGSCs) was examined using a FLIPR membrane potential assay and voltage-clamp. The dimers, in which the tertiary amines of the lidocaine moieties are linked by an alkylene chain (two to six methylene units), inhibited VGSC activator-evoked depolarization of cells heterologously-expressing rat (r) Na(v)1.2a, human (h) Na(v)1.5, and rNa(v)1.8, with potencies 10- to 100-fold higher than lidocaine (compound 1). The rank order of potency (C4 (compound 4) > C3 (compound 3) > or = C2 (compound 2) = C5 (compound 5) = C6 (compound 6) >> compound 1) was similar at each VGSC. Compound 4 exhibited strong use-dependent inhibition of hNa(v)1.5 with pIC50 values < 4.5 and 6.0 for tonic and phasic block, respectively. Coincubation with local anesthetics but not tetrodotoxin attenuated compound 4-mediated inhibition of hNa(v)1.5. These data suggest that the compound 4 binding site(s) is identical, or allosterically coupled, to the local anesthetic receptor. The dissociation rate of the dimers from hNa(v)1.5 was dependent upon the linker length, with a rank order of compound 1 > compound 5 = compound 6 > compound 2 >> compound 3. The observation that both the potency and dissociation rate of the dimers was dependent upon linker length is consistent with a multivalent interaction at VGSCs. hNa(v)1.5 VGSCs did not recover from inhibition by compound 4. However, "chase" with free local anesthetic site inhibitors increased the rate of dissociation of compound 4. Together, these data support the hypothesis that compound 4 simultaneously occupies two binding sites on VGSCs, both of which can be bound by known local anesthetic site inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339845     DOI: 10.1124/mol.105.019257

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

Review 1.  Receptor-targeting mechanisms of pain-causing toxins: How ow?

Authors:  Christopher J Bohlen; David Julius
Journal:  Toxicon       Date:  2012-04-14       Impact factor: 3.033

2.  The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  J A M Smith; D T Beattie; D Marquess; J P Shaw; R G Vickery; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-16       Impact factor: 3.000

3.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

4.  Preferential block of inactivation-deficient Na+ currents by capsaicin reveals a non-TRPV1 receptor within the Na+ channel.

Authors:  Sho-Ya Wang; Jane Mitchell; Ging Kuo Wang
Journal:  Pain       Date:  2006-09-07       Impact factor: 6.961

5.  Enhanced potency of bivalent small molecule gp41 inhibitors.

Authors:  Vladimir Sofiyev; Hardeep Kaur; Beth A Snyder; Priscilla A Hogan; Roger G Ptak; Peter Hwang; Miriam Gochin
Journal:  Bioorg Med Chem       Date:  2016-11-19       Impact factor: 3.641

6.  Classification of drugs based on properties of sodium channel inhibition: a comparative automated patch-clamp study.

Authors:  Nora Lenkey; Robert Karoly; Peter Lukacs; E Sylvester Vizi; Morten Sunesen; Laszlo Fodor; Arpad Mike
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

7.  The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.

Authors:  David T Beattie; Scott R Armstrong; Ross G Vickery; Pamela R Tsuruda; Christina B Campbell; Carrie Richardson; Julia L McCullough; Oranee Daniels; Kathryn Kersey; Yu-Ping Li; Karl H S Kim
Journal:  Front Pharmacol       Date:  2011-05-30       Impact factor: 5.810

8.  Structural basis for antiarrhythmic drug interactions with the human cardiac sodium channel.

Authors:  Phuong T Nguyen; Kevin R DeMarco; Igor Vorobyov; Colleen E Clancy; Vladimir Yarov-Yarovoy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-06       Impact factor: 11.205

Review 9.  Sodium Channels and Local Anesthetics-Old Friends With New Perspectives.

Authors:  Jannis Körner; Simone Albani; Vishal Sudha Bhagavath Eswaran; Anna B Roehl; Giulia Rossetti; Angelika Lampert
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

10.  Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway.

Authors:  Alexandra Lazar; Nora Lenkey; Krisztina Pesti; Laszlo Fodor; Arpad Mike
Journal:  Front Pharmacol       Date:  2015-09-25       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.